Scaling non-viral cell therapy approaches for solid tumor treatments
In this webinar, scientists from PACT Pharma Inc. and Thermo Fisher Scientific discuss how scalable, closed instruments can enable automation and standardization of the end-to-end manufacturing workflow—from cell isolation and activation to genetic modification and expansion.
- Scaling and automating the cell therapy manufacturing process
- Safety and regulatory advantages of non-viral transfection for cell therapy
- A highly efficient non-viral precision genome engineering process to manufacture personalized cell therapies for solid tumors